OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancers, such as ovarian and certain thyroid cancers. The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors. OXiGENE is dedicated to leveraging its scientific expertise, intellectual property and therapeutic development capabilities to bring life-extending and life-enhancing medicines to patients.
New Phase 2 Study
GI-NETs are slow-growing tumors that can spread and produce debilitating symptoms, including episodic flushing, diarrhea, wheezing, and the eventual development of carcinoid heart disease.
- OXiGENE Receives Guidance from FDA Supporting Phase 3 Trial of Fosbretabulin/Bevacizumab Combination in Platinum-Resistant Ovarian Cancer
- OXiGENE Announces Issuance of U.S. Patent for OXi4503 in Acute Myeloid Leukemia
- OXiGENE Appoints Bill Schwieterman, M.D., as President and Chief Executive Officer
After many years of research, we believe that fosbretabulin is poised to become the first commercialized VDA, having shown meaningful clinical activity and tolerability in clinical trials to date.
Vascular Disrupting Agents or “VDAs” block blood flow through established tumor blood vessels, thereby starving tumors of oxygen and essential nutrients, leading to tumor cell death.